Add to my selection

EVRYSDI (risdiplam)

Medicine - Posted on Sep 30 2021

Active substance (DCI)

risdiplam

history (1)

9/8/21

EVRYSDI 0,75 mg/ml (risdiplam)

Key points Favourable opinion for reimbursement in the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of...

CAV :
54321

icône flèche

Technical information

ATC code

M09AX10

Manufacturer

ROCHE

Presentation

EVRYSDI 0,75 mg/mL, poudre pour solution buvable
Boîte de 1 flacon de 100 mL + 1 adaptateur pour flacon + 2 seringues réutilisables de 6 mL + 2 seringues réutilisables de 12 mL (Code CIP : 34009 302 293 8 5)

All our publications

Central nervous system diseases

Congenital, genetic and rare diseases

Drug therapy

Neurodegenerative diseases

Neuromuscular diseases

Paediatrics

My account

You do not have a saved search

No element in selection

EVRYSDI (risdiplam)

EVRYSDI 0,75 mg/ml (risdiplam)

Follow us :